文献速递关节外科

改善病情抗风湿药可能降低初次全膝关节置换术后手法松解或粘连松解的风险

Disease-Modifying Antirheumatic Drugs May Reduce the Risk of Manipulation Under Anesthesia or Lysis of Adhesions Following Primary Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2025-11-14

本研究基于2013至2023年全国健康网络数据,纳入16,596例类风湿关节炎行初次全膝关节置换术患者,按术前一年内处方分为传统、生物制剂及双重改善病情抗风湿药组,并与非使用者1:1倾向评分匹配。结果显示传统改善病情抗风湿药与90天、6个月、1年及2年时手法松解或粘连松解风险降低相关,双重治疗风险降低更明显但早期翻修和假体周围感染率显著增加,生物制剂无此关联。

要点

  • 传统改善病情抗风湿药与90天至2年手法松解或粘连松解风险降低相关。
  • 双重改善病情抗风湿药治疗风险降低更明显,但早期翻修和假体周围感染率显著增加。
  • 生物制剂改善病情抗风湿药与手法松解或粘连松解无显著关联。

核心结论

  • 传统和双重改善病情抗风湿药独立地与全膝关节置换术后僵硬相关再手术率降低相关,支持其在减轻术后纤维化反应中的作用。
  • 双重治疗携带更高的假体周围感染和翻修风险。
  • 改善病情抗风湿药是预防术后僵硬的潜在药物策略,但需要前瞻性研究确认因果关系并优化围手术期管理。

研究设计与样本

  • 查询全国健康网络,纳入2013至2023年间患有类风湿关节炎并接受初次全膝关节置换术的患者。
  • 根据术前一年内处方将患者分为传统、生物制剂和双重改善病情抗风湿药组,每组使用倾向评分匹配(1:1)与非改善病情抗风湿药对照匹配,控制人口学、合并症及围手术期非甾体抗炎药和皮质类固醇使用。
  • 共纳入16,596例患者(传统组5,507例;生物制剂组929例;双重组1,862例)。

主要发现

  • 传统改善病情抗风湿药使用与90天(OR 0.73)、6个月(OR 0.66)、1年(OR 0.69)和2年(OR 0.71)时手法松解或粘连松解风险显著降低相关。
  • 双重改善病情抗风湿药治疗显示更大的风险降低(OR范围0.48至0.55),但显著增加早期翻修和假体周围感染率。
  • 生物制剂改善病情抗风湿药使用与手法松解或粘连松解无关联。
  • 所有改善病情抗风湿药组与对照组相比炎症标志物均较低。

局限性

  • 需要前瞻性研究确认因果关系并优化围手术期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stiffness is a debilitating complication following total knee arthroplasty (TKA), often necessitating manipulation under anesthesia (MUA) or arthroscopic lysis of adhesions (LOA). While nonsteroidal anti-inflammatory drugs and corticosteroids have been shown to reduce the risk of stiffness, the effect of disease-modifying antirheumatic drugs (DMARDs) remains unknown. This study aimed to evaluate whether DMARD use was associated with reduced rates of MUA or LOA after TKA. METHODS: A national health network was queried for patients who had rheumatoid arthritis and underwent primary TKA between 2013 and 2023. Patients were stratified into traditional, biologic, and dual DMARD groups based on prescriptions within one year before surgery. Each DMARD group was matched with non-DMARD controls using propensity score matching (1:1), controlling for demographics, comorbidities, and perioperative nonsteroidal anti-inflammatory drug and corticosteroid use. The primary outcome was MUA or LOA at 90 days, six months, one year, and two years. Other surgical complications and inflammatory markers were also recorded. A total of 16,596 patients were included (traditional: 5,507; biologic: 929; dual: 1,862). RESULTS: Traditional DMARD use was associated with significantly reduced MUA or LOA risk at 90 days (odds ratio (OR) 0.73), six months (OR 0.66), one year (OR 0.69), and two years (OR 0.71). Dual DMARD therapy demonstrated even greater risk reductions (OR range 0.48 to 0.55), but significantly increased early revision and periprosthetic joint infection rates. Biologic DMARD use was not associated with MUA or LOA. All DMARD groups demonstrated lower inflammatory markers compared to controls. CONCLUSIONS: Traditional and dual DMARDs were independently associated with reduced rates of stiffness-related reoperations after TKA, supporting their role in attenuating the postoperative fibrotic response. However, dual therapy carries a higher risk of periprosthetic joint infection and revision. DMARDs are a potential pharmacologic strategy to prevent postoperative stiffness, although prospective studies are needed to confirm causality and optimize perioperative management.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Goh GS, Lee S, Kim MT, et al. Disease-Modifying Antirheumatic Drugs May Reduce the Risk of Manipulation Under Anesthesia or Lysis of Adhesions Following Primary Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 41242351. doi:10.1016/j.arth.2025.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。